DelistingJul 31, 2026, 05:02 PM
Mira Pharmaceuticals Receives Nasdaq Delisting Warning
AI Summary
Mira Pharmaceuticals, Inc. received a letter from Nasdaq on July 27, 2026, indicating non-compliance with the minimum bid price requirement. The company's common stock failed to maintain a closing bid price of at least $1 for 30 consecutive business days, ending July 24, 2026. Mira Pharmaceuticals has been granted 180 calendar days, until January 25, 2027, to regain compliance by achieving a $1 bid price for at least ten consecutive business days. The letter does not result in immediate delisting, and the company plans to monitor its stock and consider options to address the deficiency.
Key Highlights
- Received Nasdaq letter on July 27, 2026, regarding minimum bid price non-compliance.
- Failed to meet Nasdaq's $1 minimum bid price requirement for 30 consecutive business days.
- The 30-day period ended on July 24, 2026.
- Granted 180 calendar days, until January 25, 2027, to regain compliance.
- Must maintain a closing bid price of at least $1 for 10 consecutive business days.
- Company will monitor stock price and consider options to resolve the deficiency.
Price Impact
More from MIRA